← Organizations
Sponsor / Institution
Hadassah Medical Organization
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs
2
linked to organization
Strong Evidence
0
0 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
0 / 2
industry vs non-industry records
Competitive Density
3
Pipeline Velocity
0
Completion Signal
0
Programs by Stage
Phase 21
Interventional/NA1
Trial / Program Status
Discontinued1
Unknown1
Modality Mix
Small Molecule2
Indication Coverage
Genetic Hearing Loss2
Hearing Loss1
Sensorineural Hearing Loss1
Syndromic Hearing Loss1
Wolfram Syndrome1
Program Types
Therapeutic2
Population Tags
genetic2
syndromic2
adult1
pediatric1
study-level1
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
2 checked · 0 open checksHadassah Wolfram Syndrome Type 2 Combination Therapy Study
Details checked
Small MoleculePhase 2Unknown
Academic Phase 2 study evaluating a combination strategy for genetically diagnosed Wolfram syndrome type 2: deferiprone chelation plus acetylcysteine antioxidant therapy, with sitagliptin/metformin added for participants with diabetes. The component drugs are trial arms/components, not separate industry-sponsored hearing-loss pipeline programs.
Data checks: institution-led-study, merged-generated-intervention-arms
Exenatide Wolfram Syndrome Study
Details checked
Small MoleculeInterventional/NADiscontinued
Withdrawn single-group interventional study of exenatide in Wolfram syndrome, a genetic syndrome that includes diabetes, optic atrophy, and deafness.
Data checks: institution-led-study, registry-verified-study